Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
17 lessons
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mResearchAdvanced
Tirzepatide vs. Semaglutide: What the 2026 Data Actually Shows
New head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.
7mProtocolsIntermediate
GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping
A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.
7mResearchAdvanced
GLP-1 Lean Mass Loss: What 2026 Data Shows
A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mResearchAdvanced
GLP-1 Nutrition Strategy: Protein, Muscle, and Labs
New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
8mProtocolsIntermediate
MOTS-C After Stopping GLP-1 Agonists: Dosing and Protocol Guide
Finished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.
9mPolicyAdvanced
Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community
For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
12mPeptidesIntermediate
GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy
GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.
9mResearchAdvanced
Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows
Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
11mPeptidesIntermediate
Semaglutide for Weight Loss: Complete Guide to GLP-1 Peptide Therapy
Explore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
10mPeptidesIntermediate
Tirzepatide: The Dual Agonist Revolution in Weight Loss
Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.
Also available at /blog for legacy links.